DocWire News: The Role of Genomic Assays in Personalizing Treatment for Early HR+ Breast Cancer
The post DocWire News: The Role of Genomic Assays in Personalizing Treatment for Early HR+ Breast Cancer appeared first on UNC Lineberger Comprehensive Cancer Center .
Read the full articleYou might also wanna read
Timing of ctDNA Testing in HR+/HER2- Advanced Breast Cancer
Conditions : Advanced Breast Cancer Sponsors : Geneplus-Beijing Co. Ltd. Recruiting
Genomic test trial suggests hormone therapy alone may be sufficient for low-risk breast cancer patients
Trial suggests patients with a low test score could be treated with hormone therapy alone with near-identical outcomes
apple.news·1mo ago
CRISPR’s next act: the companies editing the epigenome to treat disease
A feature in Nature reports how a handful of start-up firms are testing therapies that target specific epigenetic markers to treat everythin
Targeting genomic instability: From chemotherapy to precision medicine in cancer treatment
Genomic instability, a hallmark of cancer, has been targeted by treatments from chemotherapy and radiation to PARP inhibitors for repair-def
OPTIMA Trial: Genomic Testing May Allow Some High-Risk Breast Cancer Patients to Skip Chemotherapy
The Optima trial, presented at ASCO 2026, found that some with high-risk breast cancer may forgo chemotherapy. Here’s what to know.
bcrf.org·15d ago
Personalized Treatment Strategies for HER2-Positive Gastroesophageal Adenocarcinoma
Stay current with evolving strategies for HER2-positive gastroesophageal adenocarcinoman (GEA). Improve your practice with continuing educat
mdsc.pe·20d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.